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Abstract
Introduction: In squamous cell carcinoma (SCC) of the oral cavity, there is always a risk of occult metastasis
to neck nodes in the clinically and radiologically negative neck (N0). Therefore, elective neck dissection
(END) has ever been under discussion since the beginning of their routine use for the management of neck
for oral carcinomas. The purpose of the current study is to identify the percentage of occult nodal metastasis
to neck levels I-V in the cases of oral carcinoma who were treated for the N0 with END.
Methods: Patients who were treated between June 2005 and May 2010 with END from neck levels I to V for
the management of N0 with oral SCC had been identified from the database of Aga Khan University
Hospital. Those who met the inclusion and exclusion criteria were included in the study. Data were analyzed
using SPSS 16 software. Using descriptive statistics, the mean was computed for the quantitative variable
(age). Frequencies and percentages were calculated for gender, site, tumor grade, and lymph node
involvement for each neck level.
Results: A total of 50 patients were included in the study. There were 38 males and 12 females. The mean
age was 47 (range 25-72). The most common site of the tumor was buccal mucosa in 50% of the cases
followed by tongue 20%, then floor of mouth 14%, dentoalveolar ridge 8%, retromolar area 4%, lip 2%, and
hard palate 2%. Histopathological grading of tumors showed well-differentiated 28%, moderately
differentiated 33%, and poorly differentiated 6%. Twenty-seven out of 50 patients were found positive for
nodal metastasis on final postoperative histopathology. Neck node metastasis at level I was found in 22
patients, at level II in 16 patients, at level III in seven patients, and at level IV in two patients. The level V
was found free of metastasis in all of the cases.
Conclusion: The rate of occult metastatic disease to the neck nodes was similar to that found in the
literature. Both early and advanced local disease is associated with a risk of occult metastasis. END for neck
levels I-V is, therefore, recommended for the management of the N0 in all cases of oral SCCs. Spread to
levels IV and V is rare and these levels should not be a part of routine END.
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Introduction
The oral cavity is the most common site of malignant tumors of the head and neck region [1]. The most
common histological type seen in oral cavity malignancies is oral squamous cell carcinoma (OSCC) [2].
These tumors often present with nonhealing indurated lesions in the oral cavity which make the diagnosis
relatively easy to suspect but surprisingly the diagnosis of advanced disease at first presentation is not
uncommon [3]. Within the diagnosis of OSCC there exist some histological subtypes. Each of the subtypes
carries a different prognosis such as verrucous carcinoma which bears a better prognosis whereas the
basaloid type is worse [4-5]. Tumor grading into well, moderate, and poorly differentiated carcinomas is of
limited prognostic value.
Histopathological factors of prognostic importance include tumor thickness, extra-capsular spread (ECS) of
nodal metastasis, and patterns of invasion [6]. In the squamous cell carcinoma (SCC) of the oral tongue, the
tumor thickness of more than 4 mm signifies a greater than 20% risk of regional nodal metastasis [7]. Local
regional recurrence, distant metastasis, and decreased survival have been consistently reported in
association with the ECS in cervical lymph nodes. The pattern of invasion in OSCC should be reported as
cohesive, noncohesive, or widely dispersive [8]. The presence of noncohesive invasive front and perineural
invasion indicate a high risk of loco-regional relapse [9]. A crude estimate of survival for two years is around
85, 70, 50, and 40% for stage I, II, III, and IV disease respectively [10].
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The standard of care is primary surgical resection with or without adjuvant therapy. Improvements in
surgical techniques combined with the routine use of postoperative radiation or chemoradiation therapy
resulted in improved survival statistics over the last four decades. The challenges involved in the
management of such cases require a multidisciplinary approach. A final plan is reached through consensus
with the patient and carers. The overall treatment intention, either curative or palliative, needs to be clearly
communicated at the beginning. For curative intention, surgical resection should be performed and may be
followed by adjuvant therapy if indicated on the histopathological staging of the disease [11].
Even in the cases of early diagnosis with low disease burden (T1 and T2), there remains a risk of metastasis
to regional lymph nodes. Occult metastasis had been reported in more than 30% of OSCC with clinically and
radiologically negative neck (N0) [12-13]. Therefore, the decision for elective neck dissections (ENDs) for the
N0 neck turned out to be difficult and remained under discussion so far. Literature had shown the reduction
of survival by as low as 50% in the presence of neck node-positive disease which further underlines the
significance of nodal metastasis as the most significant and independent prognostic factor. The purpose of
the current study is to identify the percentage of occult nodal metastasis to neck levels I-V in the cases of
OSCC who were treated for N0 neck with END.

Materials And Methods
The database of Aga Khan University Hospital was searched to identify patients diagnosed with SCC of the
oral cavity who underwent surgical resection between June 2005 and May 2010. The criteria for inclusion and
exclusion are shown in Table 1.

Inclusion criteria

Exclusion criteria

Biopsy proven oral cavity squamous cell carcinoma

Patients who received prior radiation therapy

No radiological or clinical evidence of neck node involvement

Recurrent disease

Patients who underwent elective lymph node dissection to include level I through level V

TABLE 1: Inclusion and exclusion criteria.

Data were analyzed using SPSS 16 software. Using descriptive statistics, the mean and standard deviation
were computed for a quantitative variable (age). Frequencies and percentages were calculated for gender,
site, tumor grade, and lymph node involvement for each neck level from levels I-V.

Results
A total of 50 patients were included in the study. There were 38 males and 12 females. The mean age was 47.
The minimum age was 25 years, and the maximum age was 72 years. These variables are shown in Table 2.

Variables

Results
Male

38

Female

12

Mean

47 years

Range

25-72 years

Age

Gender

TABLE 2: Age and gender distribution.

The most common site of the tumor was buccal mucosa in 50% of the cases followed by tongue 20% then the
floor of mouth 14%, dentoalveolar ridge 8%, retromolar area 4%, lip 2%, and hard palate 2%. This is shown
in Table 3.
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Site

Number of patients

Percentage

Buccal mucosa

25

50%

Tongue

10

20%

Floor of mouth

7

14%

Dentoalveolar ridge

4

8%

Retromolar area

2

4%

Lip

1

2%

Hard palate

1

2%

TABLE 3: Site of tumor.

Histopathological grading of tumors showed well-differentiated 28%, moderately differentiated 33%, and
poorly differentiated 6%, as shown in Table 4.

Grade

Number of patients

Percentage

Well differentiated

14

28%

Moderately differentiated

33

66%

Poorly differentiated

3

6%

TABLE 4: Tumor grades.

Twenty-seven out of 50 patients found positive for nodal metastasis on final postoperative histopathology,
as shown in Table 5.

Nodal metastasis

Number of patients

Percentage

Positive

27

54%

Negative

23

46%

TABLE 5: Post-operative status of neck.

Neck node metastasis at level I was found in 22 patients, at level II in 16 patients, at level III in seven
patients, and at level IV in two patients. The level V was found free of metastasis in all of the patients. The
pattern of nodal metastasis from level I to level V is shown in Table 6.
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Neck levels

Number of patients with metastasis

Percentage

Level I

22

44%

Level II

16

32%

Level III

7

14%

Level IV

2

4%

Level V

0

0%

TABLE 6: Pattern of nodal metastasis from level I to level V.

The majority of our patients had locally advanced disease. The tumor size according to American Joint
Committee on Cancer (AJCC), 8th edition, is shown in Table 7 [14].

Tumor size

Number of patients

Percentage

T1

5

10%

T2

14

28%

T3

17

34%

T4

14

28%

TABLE 7: Tumor size.

Discussion
The critical importance of neck metastasis in OSCC for survival and locoregional control of the disease is a
widely demonstrated fact. Therefore, END has always been under discussion since the beginning of its
routine use for the management of N0 neck [15-16]. The meta-analysis of four randomized controlled trials
evaluating the disease-specific mortality rates in patients with OSCC found significantly reduced death rates
in patients who were treated with END for N0 neck [17]. Regional recurrence and poor prognosis had been
reported in greater numbers with an observation approach instead of END [18]. Smaller tumors (T1 and T2)
are equally aggressive with a reported 30% incidence of nodal metastasis [19]. In particular, the tongue and
retromolar area were found to be worse for the possibility of occult metastasis. Byers et al. reported that the
tongue was the most common site for occult metastasis [12].
In the current study, 27 out of 50 patients with radiological N0s were found positive on final histopathology
after END. The overall percentage of occult metastasis was found to be 54% which is similar to several other
studies. Jang et al. reported a 58% incidence of occult metastasis. The authors further correlated the tumor
size with occult nodal metastasis and reported significant risk in both early and advanced tumors [20].
There is no method of imaging or other examination technique except histopathology that can detect
microscopic foci of metastatic spread in cervical lymph nodes. Immunohistochemical and molecular
analysis are superior for detecting occult metastases than light microscopy with ordinary hematoxylin and
eosin staining [21-22]. When the probability of occult lymph node metastasis is more than 20%, the
guidelines recommend END [23]. However, Okura et al. recommend a probability of more than 44% as a cutoff for END [24]. Either surgery or radiation therapy can be used for the elective treatment of the N0 neck.
However, surgery offers a distinct benefit over elective radiation therapy that make surgery the method of
preferential choice. Surgery makes the pathological staging of the neck possible which will allow for better
decision making regarding the need for adjuvant therapy. If no adjuvant therapy is needed this will improve
overall quality of life [21, 25].
Metastasis to levels IV and V cervical lymph nodes is rarely seen. Therefore, neck dissection for these levels
is not routinely recommended based upon this study. The recommended procedure of choice for END is a
clearance of levels I-III, i.e. supraomohyoid neck dissection. This is also consistent with the findings in our
study where none of the patients had metastasis at level V and only 2 had metastasis at level IV [21].

Conclusions
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The findings of the current study revealed that the proportion of patients with occult neck metastasis is
considerably high not only in locally advanced cases but also in the early-stage disease. Therefore, elective
neck treatment should be considered in all cases of OSCC. Considering the patterns of occult metastasis at
each level, the selective neck dissection for levels I-III is recommended for END.
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